Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
Information source: Innovative Medical
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cataract
Intervention: Ketorolac, Nepafenac (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Innovative Medical Official(s) and/or principal investigator(s): Francis Mah, MD, Principal Investigator, Affiliation: University Pittsburgh Medical Center Eye and Ear Institute
Summary
The purpose of this study is to compare the clinical outcomes, safety and efficacy in
patients randomized to receive either ketorolac or nepafanac following cataract surgery.
Clinical Details
Official title: Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- · Male or female > 18 years of age scheduled to undergo cataract surgery
- Must be in good general health. Patients with systemic diseases will be enrolled
only if there are no ocular manifestations of their disease (ie diabetics with
normal retinal exams)
- Ability to provide informed consent and likely to complete all study visits
Exclusion Criteria:
- · Known contraindication to any study medication or any of their components
- Uncontrolled systemic disease
- Required use of ocular medications other than the study medications during the
study
- Abnormal pre-operative OCTs if obtainable
- Diabetic patients
- Use of oral NSAIDS
- Patients with ocular disease (macula degeneration, glaucoma, corneal disease)
which reduces the potential visual rehabilitation (patients will ocular disease
that will no preclude achievement of a 20/20 visual outcome may be included)..
Locations and Contacts
Dr. Francis, Pittsburgh, Pennsylvania 15213, United States
Additional Information
Last updated: June 21, 2007
|